The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort

Value in Health

Volumn 14, Issue 6, 2011, Pages 921-927

  Adams, Roisin ^a   Craig, Benjamin M ^b   Walsh, Cathal D ^a,c   Veale, Douglas J ^d   Bresnihan, Barry ^d   Fitzgerald, Oliver ^d   Barry, Michael ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

EQ 5D; scoring; SF 6D; utility

Indexed keywords

ADULT; AGED; ARTHRITIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVISED EQ 5D SCORE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY OF LIFE; QUESTIONNAIRES; YOUNG ADULT;

EID: 80052729508     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.03.002     Document Type: Article

References (46)

1. E. Yelin, L. Callahan National Arthritis Data Work Group The economic cost and social psychological impact of musculoskeletal conditions Arthritis Rheum 38 1995 1351 1356
2. C. Ackermann, and A. Kavanaugh Economic burden of psoriatic arthritis Pharmacoeconomics 26 2008 121 129
3. Guide to the Methods of Technology Appraisal 2008 NICE London
4. Guidelines for the Economic Evaluation of Health Technologies: Canada 2006 2009 Canadian Agency for Drugs and Technologies in Health (CADTH) Ottawa, Ontario, Canada
5. The Norwegian Medicines Control Authority Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement http://www.ispor.org/peguidelines/countrydet.asp?c=15&t=1 Accessed July 30, 2009
6. J. Rovira, and F. Antoanzas Economic analysis of health technologies and programmes A Spanish proposal for methodological standardisation Pharmacoeconomics 8 1995 245 252
7. D. Arnold, A. Girling, A. Stevens, and R. Lilford Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis BMJ 339 2009 b2688
8. EUROQoL www.euroqol.org Accessed December 20, 2010
9. J. Brazier, J. Roberts, and M. Deverill The estimation of a preference-based measure of health from the SF-36 J Health Econ 21 2002 271 292 (Pubitemid 34143147)
10. P.J. Mease, D.D. Gladman, and C.T. Ritchlin Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 2005 3279 3289 (Pubitemid 41447111)
11. D. Van Der Heijde, L. Klareskog, and A. Singh Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial Ann Rheum Dis 65 2006 328
12. M.S. Heiberg, C. Kaufmann, and E. Rodevand The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study Ann Rheum Dis 66 2007 1038 1042 (Pubitemid 47122316)
13. M. Kimel, M. Cifaldi, N. Chen, and D. Revicki Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA J Rheumatol 35 2008 206
14. A.M. van Gestel, M.L.L. Prevoo, and M.A. van't Hof Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria Arthritis Rheum 39 1996 34 40 (Pubitemid 26036375)
15. J. Fries, P. Spitz, and D. Young The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales J Rheumatol 9 1982 789 793
16. N. Hurst, P. Kind, and D. Ruta Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D) Rheumatology 36 1997 551 559
17. J.E. Ware, and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection Med Care 30 1992 473 483
18. D.L. Scott, B. Khoshaba, E.H. Choy, and G.H. Kingsley Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ Ann Rheum Dis 66 2007 1534 1537 (Pubitemid 350032666)
19. C.A. Marra, A.A. Rashidi, and D. Guh Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 14 2005 1333
20. S. Bryan, and L. Longworth Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur J Health Econ 6 2005 253 260 (Pubitemid 41638849)
21. R. Adams, C. Walsh, and D.J. Veale Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis Pharmacoeconomics 28 2010 477 487
22. T. Sach, G. Barton, and C. Jenkinson Comparing cost-utility estimates: does the choice of EQ-5D or SF-6D matter? Med Care 47 2009 889 894
23. A. Williams A measurement and valuation of health: a chronicle Discussion Paper 1995 Centre for Health Economics, York Health Economics Consortium, NHS Centre for Reviews & Dissemination, University of York York
24. A. Brennan, N. Bansback, and R. Nixon Modelling the cost effectiveness of TNF-a inhibitors in the management of rheumatoid arthritis: results form the British Society for Rheumatology Biologics Registryan independent report Rheumatology 46 2007 1345-4
25. M.J. Harrison, M. Lunt, and N. Bansback The Validity of Estimating EQ-5D and SF-6D Utility Values from the HAQ American College of Rheumatology Annual Meeting,San Francisco, CA October 2429, 2008
26. G. Barton, T. Sach, and M. Doherty An assessment of the discriminative ability of the EQ-5D index, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions Euro J Health Econ 9 2008 237
27. B. Craig, and J. Busschbach The episodic random utility model unifies time trade-off and discrete choice approaches in health state valuation Popul Health Metr 7 2009 3
28. M.J. Harrison, L.M. Davies, and N.J. Bansback Why Do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An investigation of the EQ-5D classification system Value Health 12 2009 1026 1034
29. C.A. Marra, S.A. Marion, and D.P. Guh Not all "quality-adjusted life years" are equal J Clin Epidemiol 60 2007 616
30. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095
31. P. van Riel, A. van Gestel, and L. van de Putte Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers Br J Rheumatol 35 Suppl. 2 1996 4 7
32. S. Kharroubi, J.E. Brazier, and A. O'Hagan Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method Soc Sci Med 64 2007 1242
33. University of Sheffield Health Economics and Decision Science Bayesian programme [online] http://www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d/ bayesian.html Accessed June 1, 2010
34. N. Hurst, P. Jobanputra, and M. Hunter Validity Of EuroQoLa generic health status instrument - in patients with rheumatoid arthritis: economic and health outcomes research group Rheumatol 33 1994 655-2
35. J. Kekow, R.J. Moots, and P. Emery Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial Ann Rheum Dis 69 2010 222 225
36. P. Lindgren, P. Geborek, and G. Kobelt Modelling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden Int J Technol Assess Health Care 25 2009 181 189
37. B.M. Craig, and J.J.V. Busschbach Toward a more universal approach in health valuation Health Econ Epub 2010 Aug 2]
38. B.M. Craig, J.J.V. Busschbach, and J.A. Salomon Modeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methods Medical Care 47 2009 634 641
39. National Institute for Clinical Excellence Final appraisal determination Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (part review of NICE technology appraisal guidance 36, review of NICE technology appraisal guidance 126 and 141 http://www.nice.org.uk/nicemedia/live/12135/49473/49473.pdf Accessed November 10, 2010
40. D.L. Patrick, H.E. Starks, and K.C. Cain Measuring preferences for health states worse than death Med Decis Making 14 1994 9 18 (Pubitemid 24032677)
41. M. Harrison, L. Davies, and N. Bansback The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis Qual Life Res 18 2009 1195 1205
42. J. Brazier, J. Roberts, A. Tsuchiya, and J. Busschbach A comparison of the EQ-5D and SF-6D across seven patient groups Health Econ 13 2004 873 884 (Pubitemid 39264234)
43. C.A. Marra, J.C. Woolcott, J.A. Kopec, and K. Shojania A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis Soc Sci Med 60 2005 1571
44. P. Prescott-Clarke, and P. Primatesta Health Survey for England 1996. Vol 1: Findings; Vol 11: Survey Methodology and Documentation 1998 The Stationary Office London
45. M.J. Harrison, L.M. Davies, and N.J. Bansback Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An investigation of the EQ-5D classification system Value Health 12 2009 1026 1034
46. J.W. Shaw, J.A. Johnson, and S.J. Coons US valuation of the EQ-5D health states: development and testing of the D1 valuation model Med Care 43 2005 203 220 (Pubitemid 40353904)